InMed Pharmaceuticals Income Statement (2021-2025) | INM

Income Statement Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.31M0.51M0.32M0.47M1.03M2.31M0.90M1.24M1.17M1.28M1.26M1.11M1.26M1.30M1.12M
Cost of Revenue 0.13M0.27M0.24M0.34M0.84M1.32M0.88M0.92M0.88M0.82M0.77M0.65M1.09M0.73M0.72M
Gross Profit 0.18M0.25M-0.49M0.13M0.19M1.57M0.02M0.32M0.29M0.47M0.49M0.46M0.18M0.58M0.40M
Operating items
Depreciation & Amortization - Total 0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M
Research & Development 1.49M2.54M1.75M1.50M1.38M0.85M0.88M0.62M1.29M0.61M0.66M0.66M0.70M1.06M0.91M0.11M0.58M
Selling, General & Administrative 1.37M1.84M1.92M1.74M1.56M1.46M1.41M1.41M1.30M1.36M1.37M1.76M1.49M1.55M1.33M2.25M1.53M
Restructuring Costs 0.07M0.03M-0.08M0.01M0.01M0.10M
Other Operating Expenses 0.03M-2.88M-3.39M-8.79M0.15M-0.04M0.01M0.09M0.09M-0.03M0.08M-0.03M0.02M0.09M0.06M0.02M0.11M
Operating Expenses 2.89M4.42M3.72M6.77M3.08M2.35M2.34M2.06M2.69M1.97M2.13M2.50M2.23M2.71M2.31M2.40M2.22M
Operating Income -3.54M-6.52M-3.58M-2.21M-2.15M-0.49M-2.67M-1.64M-1.84M-2.03M-1.73M-2.25M-2.14M-1.82M-1.82M
EBIT -2.97M-4.28M-3.54M-6.52M-3.58M-2.21M-2.15M-0.49M-2.67M-1.64M-1.84M-2.03M-1.73M-2.25M-2.14M-1.82M-1.82M
Non-operating items
Interest & Investment Income 0.01M0.03M0.03M0.03M0.07M0.12M0.16M0.15M0.14M0.17M0.12M0.10M0.06M0.03M0.02M0.05M0.09M
Other Non Operating Income -0.08M0.00M0.03M-0.07M-0.10M0.02M-0.00M0.03M-0.05M0.06M-0.05M-0.03M0.02M-0.05M-0.02M0.02M-0.06M
Non Operating Income 0.16M0.15M0.12M0.10M
Net income details
EBT -2.97M-4.28M-3.48M-7.87M-3.50M-2.10M-2.00M-0.34M-2.54M-1.48M-1.72M-1.93M-1.68M-2.58M-2.12M-1.79M-1.73M
Tax Provisions 0.01M
Profit After Tax -2.97M-2.97M-3.48M-7.87M-3.51M-2.10M-2.00M-0.34M-2.54M-1.48M-1.72M-1.96M-1.70M-2.58M-2.12M-1.80M-1.73M
Income from Continuing Operations -2.97M-4.28M-3.48M-7.87M-3.51M-2.10M-2.00M-0.34M-2.54M-1.48M-1.72M-1.93M-1.68M-2.58M-2.12M-1.79M-1.73M
Consolidated Net Income -2.97M-4.28M-3.48M-7.87M-3.51M-2.10M-2.00M-0.34M-2.54M-1.48M-1.72M-1.93M-1.68M-2.58M-2.12M-1.79M-1.73M
Income towards Parent Company -2.97M-4.28M-3.48M-7.87M-3.51M-2.10M-2.00M-0.34M-2.54M-1.48M-1.72M-1.93M-1.68M-2.58M-2.12M-1.79M-1.73M
Net Income towards Common Stockholders -2.97M-4.28M-3.48M-7.87M-3.51M-2.10M-2.00M-0.34M-2.54M-1.48M-1.72M-1.93M-1.68M-2.58M-2.12M-1.79M-1.73M
Additional items
EPS (Basic) -6.17-7.73-6.14-13.04-4.06-0.91-0.600.28-15.24-3.71-3.58-3.66-2.71-3.64-1.94-0.43-0.44
EPS (Weighted Average and Diluted) -6.14-0.14-15.24-3.71-3.58-3.66-2.71-3.64-1.94-0.43-0.44
Shares Outstanding (Weighted Average) 0.02M0.03M0.03M0.03M0.05M0.05M0.17M0.17M0.17M0.26M0.30M0.42M0.67M0.72M1.21M1.21M2.38M
Shares Outstanding (Diluted Average) 0.57M2.45M0.17M0.40M0.48M0.38M0.62M0.71M1.10M0.98M3.95M
EBITDA -2.97M-4.28M-3.48M-7.87M-3.51M-2.10M-2.00M-0.47M-2.66M-1.63M-1.83M-2.03M-1.72M-2.24M-2.13M-1.81M-1.82M